What is the prevalence of Hidradenitis Suppurativa?

TL;DR: Hidradenitis Suppurativa is a chronic inflammatory skin condition with an estimated global prevalence ranging from 0.05% to 4.1%, though precise figures vary significantly due to widespread underdiagnosis and diagnostic delays. It most commonly presents in early adulthood, disproportionately affects females, and is frequently under-reported in clinical literature.

What is the estimated prevalence of Hidradenitis Suppurativa?

Determining the exact prevalence of Hidradenitis Suppurativa is challenging because the condition is frequently misdiagnosed as simple boils or folliculitis. According to data from the NIH Genetic and Rare Diseases Information Center (GARD) and various epidemiological studies, estimates vary widely, often cited between 0.05% and 4.1% of the population. Because of the stigma associated with the disease and the high rate of clinical misdiagnosis, many experts believe the true prevalence of Hidradenitis Suppurativa is likely higher than current diagnostic codes suggest.

Who is most likely to develop Hidradenitis Suppurativa?

The demographic distribution of Hidradenitis Suppurativa shows distinct patterns in gender and age of onset:

• Gender: Research consistently indicates that females are more frequently diagnosed with Hidradenitis Suppurativa than males, with reported ratios often ranging from 2:1 to 3:1.


• Age of Onset: While it can appear at any age, the disease typically manifests after puberty, most commonly between the ages of 20 and 40. Pediatric cases are rare, and onset after age 50 is also less common.


• Geographic and Ethnic Variation: While Hidradenitis Suppurativa is recognized worldwide, some studies suggest a higher prevalence among individuals of African and African-American descent, though further research is required to distinguish between genetic predisposition and socioeconomic diagnostic disparities.

Why is accurate data for Hidradenitis Suppurativa difficult to obtain?

The primary barrier to gathering accurate statistics is the "diagnostic odyssey" many patients experience. On average, it can take several years for a patient to receive a formal diagnosis of Hidradenitis Suppurativa after their first symptoms appear. During this time, the disease may be logged in medical records as recurrent abscesses or general skin infections, leading to a significant undercount in epidemiological databases. Furthermore, the DiseaseMaps.org community, which currently includes 729 members living with Hidradenitis Suppurativa, provides a vital, real-world perspective that often captures the experiences of those who have struggled to get an accurate diagnosis within the traditional healthcare system.

Is Hidradenitis Suppurativa considered a rare disease?

The classification of Hidradenitis Suppurativa as "rare" depends on the region and the specific diagnostic criteria used. In many jurisdictions, it is categorized as a chronic, debilitating inflammatory disease rather than a rare one. However, due to its complexity and the systemic impact it has on the immune, skeletal, and endocrine systems, it is often managed by specialists who handle rare and complex dermatological conditions. The clinical burden of the disease is significant, often requiring multidisciplinary care to manage the high risk of secondary complications like cellulitis or, in long-standing cases, squamous cell carcinoma.

Next steps

• Consult a board-certified dermatologist who specializes in inflammatory skin conditions or Hidradenitis Suppurativa.


• Maintain a symptom journal to track flare-ups, which can assist your physician in determining the severity and appropriate treatment plan.


• Join the DiseaseMaps.org community to connect with other patients and share experiences regarding management strategies.


• Request a referral to a wound care specialist if you are experiencing persistent, non-healing lesions.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hidradenitis Suppurativa.


• Orphanet: Rare Disease Database (ORPHA: 399).


• PubMed: "Epidemiology of Hidradenitis Suppurativa: A Systematic Review" (Current clinical literature).


• DiseaseMaps.org: Community patient data and registry insights.